Is Pediatrix Medical Group, Inc. (NYSE:MD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Pediatrix Medical Group, Inc. at current levels.
A boring, restructured NICU operator throwing off $164M in cash at 10x earnings while the market still trades it like a melting ice cube.
Where MD is headed
Pediatrix in 2028 looks almost nothing like the MEDNAX wreck that traded at $11 a year ago. The portfolio rationalisation, exiting unprofitable office practices, ditching the anaesthesia and radiology disasters of the prior decade, walking away from money-losing hospital contracts, is mostly done. What's left is a focused neonatology and maternal-fetal medicine business with roughly 380 NICU contracts, the largest network of affiliated neonatologists in the United States, and a recurring fee structure tied to one of the least cyclical demand pools in healthcare: babies who need intensive care the day they're born. That demand doesn't flex with the unemployment rate. It barely flexes with insurance cycles. It shows up.
Read the full Compass Direction on MD
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $22.47).
See the full MD analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Pediatrix Medical Group, Inc. (NYSE:MD) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Pediatrix Medical Group, Inc. at current levels. A boring, restructured NICU operator throwing off $164M in cash at 10x earnings while the market still trades it like a melting ice cube.
What is MD's Compass Score?
Pediatrix Medical Group, Inc. scores 78/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for MD?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the MD page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.